Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for ...
17 Enero 2018 - 6:00AM
Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines
company, announced today that it is extending its partnership with
Takeda Pharmaceutical Company Limited (TSE:4502) (Takeda).
Under the collaboration, Takeda and Arcturus will advance their
efforts to develop RNA-based therapeutics for the treatment of
non-alcoholic steatohepatitis (NASH) and other gastrointestinal
(GI) related disorders using Arcturus’s wholly-owned LUNAR™
lipid-mediated delivery systems and UNA Oligomer chemistry.
“This agreement with Takeda represents their continued
commitment to our technology and development programs,” said Joseph
Payne, president and chief executive officer of Arcturus.
“Arcturus’s expertise and intellectual property in the field of RNA
medicines is complemented by Takeda’s extensive clinical
development experience in the GI field. Together, we aim to bring
new treatments to patients with NASH and other GI disorders.”
About Arcturus Therapeutics Ltd. Founded in
2013 and based in San Diego, Arcturus Therapeutics Ltd.
(NASDAQ:ARCT) is an RNA medicines company with enabling
technologies – UNA Oligomer chemistry and LUNAR™ lipid-mediated
delivery. Arcturus's diverse pipeline of RNA therapeutics includes
programs pursuing rare diseases [Glycogen Storage Disease type
III (GSDIII), ornithine transcarbamylase
(OTC) deficiency], Hepatitis B, non-alcoholic steatohepatitis
(NASH), cystic fibrosis, and vaccines. Arcturus’s versatile RNA
therapeutics platforms can be applied toward multiple types of RNA
medicines including small interfering RNA, messenger RNA, replicon
RNA, antisense RNA, microRNA and gene editing therapeutics.
Arcturus owns LUNAR lipid-mediated delivery and Unlocked
Nucleomonomer Agent (UNA) technology including UNA Oligomers, which
are covered by its extensive patent portfolio (120 patents and
patent applications, issued in the U.S., Europe, Japan, China and
other countries). Arcturus’s proprietary UNA technology can be used
to target individual genes in the human genome, as well as viral
genes, and other species for therapeutic purposes. Arcturus’s
commitment to the development of novel RNA therapeutics has led to
partnerships with Janssen Pharmaceuticals, Inc., part of the
Janssen Pharmaceutical Companies of Johnson &
Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, Synthetic Genomics Inc.,
CureVac AG and Cystic Fibrosis Foundation Therapeutics
Inc. For more information, visit www.ArcturusRx.com, the
content of which is not incorporated herein by reference.
Forward-looking Statements This press
release contains “forward-looking statements” that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
All statements, other than statements of historical facts, included
in this press release regarding strategy, future operations,
collaborations, prospects, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Arcturus’s continued
listing on the Nasdaq Global Market; Arcturus’s future operations
and its ability to successfully initiate and complete clinical
trials; the nature, strategy and focus of Arcturus; the development
and commercial potential and potential benefits of any product
candidates of Arcturus; and the continuation or modification of
collaborative arrangements. Arcturus may not actually achieve the
plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Such statements are based on management’s current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including
without limitation, an inability to develop and market product
candidates.
The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties,
including those discussed in Arcturus’s filings with the SEC.
Except as otherwise required by law, Arcturus disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
ContactsArcturus
Therapeutics858-900-2666IR@ArcturusRx.com
Andrew McDonald Ph.D.LifeSci Advisors LLC646-597-6979
Source: Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024